Sartorius AG Adjusts Fiscal Year 2024 Guidance and Reports H1 2024 Results

Sartorius AG has revised its guidance for fiscal year 2024 due to a volatile market environment, despite a positive trend in H1 sales. Sales revenue for the first half of the year saw a slight decline to €1,680 million, with a reported decrease of 3.2%. However, Q2 sales increased by 3.6%. Order intake rose by 8.5% to €1,558 million.

Regional performance varied, with the EMEA region showing a 3.6% increase in sales, while the Americas and Asia/Pacific recorded declines of 6.5% and 4.7%, respectively. The Group’s underlying EBITDA fell by 8.8% to €471 million, resulting in a margin of 28.1%.

Sartorius employed 14,143 people at the end of June 2024, marking a reduction from the previous year. Net operating cash flow was €347 million, and capital expenditures totaled €239 million. The company’s balance sheet remains strong, with an equity ratio of 38.3%.

The Bioprocess Solutions Division saw stable sales and an 11.7% increase in order intake, while the Lab Products & Services Division experienced an 8.9% decline in sales. Both divisions anticipate stable sales levels for the remainder of the year, with slight positive to negative deviations.

Sartorius projects sales revenue for 2024 to remain at prior-year levels, with an EBITDA margin of 27-29%. Despite current challenges, the company maintains positive long-term growth prospects in the life science and biopharmaceutical markets.